UPDATE AND ANALYSIS OF THE UCL PRO-PROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE9 GENE (PCSK9) VARIANT DATABASE

被引：0
|
作者：
Leigh, S. E. A. [1 ]
Lee, Y. Ping [1 ]
Whittall, R. A. [1 ]
Dawson, N. [1 ]
Das, S. [1 ]
Martin, A. C. R. [1 ]
Orengo, C. A. [1 ]
Humphries, S. E. [1 ]
机构：
[1] UCL, London, England
来源：
ATHEROSCLEROSIS | 2014年 / 235卷 / 02期
关键词：
D O I：
10.1016/j.atherosclerosis.2014.05.262
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EAS-0812
引用
收藏
页码：E98 / E98
页数：1
相关论文
共 50 条
  • [1] PRO-PROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE9 (PCSK9) VARIANT DATABASE: PRELIMINARY ANALYSIS
    Leigh, S. E.
    Jakubcova, T.
    Whittall, R. A.
    Humphries, S. E.
    ATHEROSCLEROSIS, 2009, 207 (01) : E9 - E9
  • [2] Pro protein convertase subtilisin kexin type 9 (PCSK9) inhibitors Pharmacological review and update
    Corral, Pablo
    Suter, Agustina
    Rusconi, Alejandro
    Trigo, Leandro
    INSUFICIENCIA CARDIACA, 2016, 11 (03) : 122 - 129
  • [3] Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition
    Wierzbicki, Anthony S.
    Grant, Paul
    CLINICAL MEDICINE, 2016, 16 (04) : 353 - 357
  • [4] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
    Avci, Ahmet
    Demir, Kenan
    Altunkeser, Bulent Behlul
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
  • [5] Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells
    Amjad Ali
    Hema Unnikannan
    Jasmin Shafarin
    Khuloud Bajbouj
    Jalal Taneera
    Jibran Sualeh Muhammad
    Haydar Hasan
    Albert Salehi
    Samir Awadallah
    Mawieh Hamad
    Endocrine, 2022, 76 : 543 - 557
  • [6] Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells
    Ali, Amjad
    Unnikannan, Hema
    Shafarin, Jasmin
    Bajbouj, Khuloud
    Taneera, Jalal
    Muhammad, Jibran Sualeh
    Hasan, Haydar
    Salehi, Albert
    Awadallah, Samir
    Hamad, Mawieh
    ENDOCRINE, 2022, 76 (03) : 543 - 557
  • [7] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
    Leong, Derek
    Wu, Peter E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (32) : E894 - E894
  • [8] PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): A Narrative Review
    Dua, Pamila
    Reeta, K. H.
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2020, 6 (03) : 226 - 233
  • [9] Regulation of ENaC by proprotein convertase subtilisin/kexin type 9(PCSK9)
    Sharotri, Vikas
    Snyder, Peter M.
    FASEB JOURNAL, 2010, 24
  • [10] Loss of the association between plasma Pro-protein Convertase Subtilisin/Kexin type 9 (PCSK9) and LDL-apoB100 catabolism in type 2 diabetes
    Verges, B.
    Costet, P.
    Duvillard, L.
    Brindisi, M. -C.
    Krempf, M.
    Cariou, B.
    DIABETOLOGIA, 2010, 53
12345